Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27852083)
Watch
English
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
23414587
retrieved
13 November 2016
title
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
(English)
1 reference
stated in
PubMed
PubMed ID
23414587
retrieved
13 November 2016
author
Dirk Schadendorf
series ordinal
2
0 references
Axel Hauschild
series ordinal
8
0 references
Reinhard Dummer
series ordinal
15
0 references
Paolo Antonio Ascierto
series ordinal
1
object named as
Paolo A Ascierto
0 references
Christian U Blank
series ordinal
7
object named as
Christian U Blank
0 references
author name string
Carola Berking
series ordinal
3
0 references
Sanjiv S Agarwala
series ordinal
4
0 references
Carla Ml van Herpen
series ordinal
5
0 references
Paola Queirolo
series ordinal
6
0 references
J Thaddeus Beck
series ordinal
9
0 references
Annie St-Pierre
series ordinal
10
0 references
Faiz Niazi
series ordinal
11
0 references
Simon Wandel
series ordinal
12
0 references
Malte Peters
series ordinal
13
0 references
Angela Zubel
series ordinal
14
0 references
publication date
March 2013
0 references
published in
Lancet Oncology Commission
0 references
volume
14
0 references
page(s)
249-56
0 references
issue
3
0 references
cites work
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
NRAS mutation status is an independent prognostic factor in metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The European Academy of Cancer Sciences
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improved survival with MEK inhibition in BRAF-mutated melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MEK1 mutations confer resistance to MEK and B-RAF inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Distinct sets of genetic alterations in melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Somatic activation of KIT in distinct subtypes of melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRAF mutation predicts sensitivity to MEK inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(13)70024-X
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
32851
OpenCitations bibliographic resource ID
32851
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
32851
PubMed ID
23414587
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
32851
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
